Table of Contents Author Guidelines Submit a Manuscript
International Journal of Endocrinology
Volume 2010, Article ID 820876, 6 pages
Research Article

Effect of Glucose or Fat Challenge on Aspirin Resistance in Diabetes

1Division of Endocrinology, Department of Medicine, Arizona Health Sciences Center, University of Arizona, 1656 E Mabel Street, Tucson, AZ 85724, USA
2Cardiovascular and Thoracic Surgery and the Sarver Heart Center, Arizona Health Sciences Center, University of Arizona, Tucson, AZ 85724, USA
3Southern Arizona VA Health Care System, Tucson, AZ 85723, USA

Received 29 July 2010; Accepted 1 December 2010

Academic Editor: Dariush Elahi

Copyright © 2010 Hussein N. Yassine et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Aspirin has lower antiplatelet activity in diabetic patients. Our aim is to study the roles of acute hyperglycemia and hyperlipidemia on aspirin function in diabetic subjects with and without cardiovascular disease. Using urine thromboxane (pg/mg creatinine) and VerifyNow (Aspirin Resistance Measures-ARU), we investigated diabetic subjects during a 2-hour glucose challenge ( ) or a 4-hour fat challenge ( ). All subjects were currently taking aspirin (81 or 325 mg). After fat ingestion, urine thromboxane increased in all subjects (Mean ± SE before: after) ( : , ), while we noted a trend increase in VerifyNow measures ( : , ). The response to glucose ingestion was variable. Diabetic subjects with cardiac disease and dyslipidemia increased thromboxane ( : , ) and VerifyNow ( : , ) measures after glucose. We conclude that saturated fat ingestion increases in vivo thromboxane production despite aspirin therapy.